Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP - Wikidata - wikimedia - TriplyDB

Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP

Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP

http://www.wikidata.org/entity/Q35436566

about

Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expression Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells.Differentiation of human bone marrow stem cells into cells with a neural phenotype: diverse effects of two specific treatments The role of phosphodiesterase-5 inhibitors in prostatic inflammation: a review Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure The many faces of neuroendocrine differentiation in prostate cancer progression β-Adrenergic Receptor Signaling in Prostate Cancer Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression Expression of PDE11A in normal and malignant human tissues p21-Activated kinase 4 promotes prostate cancer progression through CREB Activated 3',5'-cyclic AMP-dependent protein kinase is sufficient to induce neuroendocrine-like differentiation of the LNCaP prostate tumor cell line.Inhibition of tumor cell motility by the interferon-inducible GTPase MxA Neuroendocrine differentiation of human prostatic primary epithelial cells in vitro.Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival.Role of stimulatory guanine nucleotide binding protein (GSalpha) in proliferation of PC-3M prostate cancer cells.Expression of basal cell keratins in human prostate cancer metastases and cell lines.Roles of db-cAMP, IBMX and RA in aspects of neural differentiation of cord blood derived mesenchymal-like stem cells.Neuroendocrine differentiation in prostatic carcinoma.The molecular basis for ethnic variation and histological subtype differences in prostate cancer.Overexpression of an alpha 1H (Cav3.2) T-type calcium channel during neuroendocrine differentiation of human prostate cancer cells.The steroid receptor coactivator-3 is required for developing neuroendocrine tumor in the mouse prostate The deprivation syndrome is the driving force of phylogeny, ontogeny and oncogeny.Targeting CREB for cancer therapy: friend or foe Stem cell differentiation within the human prostate epithelium: implications for prostate carcinogenesis.Involvement of fatty acid-CoA ligase 4 in hepatocellular carcinoma growth: roles of cyclic AMP and p38 mitogen-activated protein kinase.Cytoskeleton reorganization as an alternative mechanism of store-operated calcium entry control in neuroendocrine-differentiated cells.Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.Prostate cancer and neuroendocrine differentiation: more neuronal, less endocrine?Ionizing radiation induces neuroendocrine differentiation of prostate cancer cells in vitro, in vivo and in prostate cancer patients A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.Neuroendocrine differentiation in human prostatic tumor models EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt Up-Regulated Expression of LAMP2 and Autophagy Activity during Neuroendocrine Differentiation of Prostate Cancer LNCaP Cells Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model.Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention.Clinical implications of neuroendocrine differentiation in prostate cancer.Nonreceptor tyrosine kinases in prostate cancer.

P2860

Q22254649-261E60E5-3674-45CC-9AED-87D45D2CF249 Q24319902-6867CDC2-28B3-48B4-B1ED-8521639E4DC9 Q24622202-E56DFCCC-37D9-4821-B644-2777F1CFCCF2 Q24746249-0337D264-A662-4A8E-8694-9558182F0CD7 Q24746259-67CD4EAA-227C-4FD1-87C2-13BF33DD33F5 Q25257214-648C91D3-8558-4CA4-A8B2-6DF43BE52F2C Q26785428-58BD9BCE-E5D5-4782-85A3-2CDEBAFB9C81 Q26859201-D5F5D672-D534-46CC-8AEA-308BAF57926F Q26992049-77CBF0B5-3020-4DB6-9962-1EE701E0078C Q28084943-D99C0F2F-AD3F-40CE-99D4-FEF39EEB61C9 Q28257270-360D43F5-DD5C-4370-ABD6-ED130E788128 Q28259848-9EFD4772-FEE7-43AE-8BCC-5EA48E3D5BB8 Q28269126-54657AAA-4707-492B-9BED-09627A90A6EE Q30305599-5F355FE9-9C5A-4BB7-B70B-D33801E6E23C Q30487769-75D4FC98-3CBD-47D2-A711-98CDBC4C687D Q30850776-23A585C8-8206-469A-B32D-E1855CC6465D Q30940949-72C9D4F6-050C-48E1-BD73-9D5053775B50 Q31811708-51B8F8C4-7251-4578-85DC-399B0795F50B Q32048563-BE0DA200-A219-4362-8B1D-F0B329A35DB1 Q33535922-8F0C02E5-E914-4306-9D12-FC13EF4F483B Q33604393-EF55CBBB-9222-4F2D-A459-09ACEBACCAB5 Q33835864-6B889B4B-C4FD-4603-BA40-CDFD6D3F56A2 Q34110103-CBBCBAFF-2963-485E-B165-F469D1CA4375 Q34365187-79B19659-18C8-435C-BCF3-BBB433C15F24 Q34371685-9001506E-C90A-49C9-93AC-2C34988BABB4 Q34387213-5ED6AEEF-C60E-4DEB-B189-F72604511D14 Q34394076-079200F7-F671-497A-9B3E-542641F2F475 Q34413542-F91CC2FD-4319-4129-A12B-B4BDEE40F8DC Q34438254-2DC54B49-592E-4598-AA6F-8F83CE6626CE Q34959208-CCA6589A-77C2-4F29-B702-F4C927411CF8 Q35141115-72BDB169-AD00-411E-A003-923DB2E9726D Q35380936-B08D2DC1-8E18-49B3-A902-BFDBEB9397CF Q35576853-EE0A7E1F-3067-4584-BB63-1DB8743752B2 Q35782075-3F9F8D5E-3520-4135-84C6-2793133D4DBB Q35945055-9E3CA1E1-EFD2-425F-AA15-37C76A495F1A Q36132777-120075FE-10A1-44CC-B05F-2AE4279B4AAB Q36143611-FCB0FB96-E43E-4CDC-AC62-A58E2532D255 Q36397666-1EA3A90C-4BCE-4A7F-9D5E-891FC6E78AC0 Q36639877-22023B2A-66E1-4E80-B825-E9A9B252E6E8 Q36759212-2D4032BB-8FB7-430F-812C-6FE5CF0CB764

P2860

Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP

http://www.wikidata.org/entity/Q35436566

description

1994 nî lūn-bûn

@nan

1994 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

1994 թվականի հունիսին հրատարակված գիտական հոդված

@hy

1994年の論文

@ja

1994年論文

@yue

1994年論文

@zh-hant

1994年論文

@zh-hk

1994年論文

@zh-mo

1994年論文

@zh-tw

1994年论文

@wuu

name

Terminal neuroendocrine differ ...... eased intracellular cyclic AMP

@ast

Terminal neuroendocrine differ ...... eased intracellular cyclic AMP

@en

type

label

Terminal neuroendocrine differ ...... eased intracellular cyclic AMP

@ast

Terminal neuroendocrine differ ...... eased intracellular cyclic AMP

@en

prefLabel

Terminal neuroendocrine differ ...... eased intracellular cyclic AMP

@ast

Terminal neuroendocrine differ ...... eased intracellular cyclic AMP

@en

P1433

Q35436566-2ACC15CA-EA9D-4F03-AB06-CF98DC850CBE

P1476

Q35436566-F300D6EB-D519-457F-989E-C8B259A8306B

P2093

Q35436566-0CCE808B-735F-4973-B2C0-DA042C161D2B

Q35436566-151B9641-C821-47A5-A3B5-D46E6D995B3C

Q35436566-492E34D6-0BAA-4D2D-96AB-7B2BCF057733

Q35436566-567FC300-1320-4828-AF6C-7F378B7436C4

Q35436566-6A5BE9F4-3503-4C1F-A12D-6F342A8A5F16

Q35436566-6D4D5032-CE45-4CF4-AF6D-1970D0A713BD

Q35436566-9DC60879-B6AB-4B16-A312-3ED758AFDB23

Q35436566-A6650750-8F1C-4941-9648-A46FDF5569B7

Q35436566-CE81881B-F086-4340-B7DB-83F34D1D4DB4

Q35436566-D12728BE-9A1B-4E1F-9D5A-C147079B4599

P2860

Q35436566-0334E006-6B55-43B3-8545-DFF0C0F7D761

Q35436566-078A4604-FD7A-4898-B489-1F9C4D007E1D

Q35436566-13144AFA-1CB2-4761-8A63-656D1E3D59E9

Q35436566-30B4443F-7621-4E20-BF03-0053614A3938

Q35436566-443B61DB-861D-4765-B1B1-85CBB2F2A365

Q35436566-52469670-5E7A-442C-B4CB-39E9858C24F6

Q35436566-7272D00A-D56E-4A24-BDCC-AEB6B39ED6C7

Q35436566-82C417A4-C55B-44DA-B0C1-D284C3AB7395

Q35436566-88961733-C696-4D49-80B1-9C50A2FEA8A7

Q35436566-B0D9566F-1A66-4C49-8741-9647B217BA24

P304

Q35436566-A214C549-4BD5-470A-AFE7-0ED34E3ED4E5

P31

Q35436566-E7CA48C9-21C3-42E6-9CC5-1A070FEF082B

P356

Q35436566-8C239918-99B5-49A1-A9EF-4CA8BF08DA66

P407

Q35436566-69541E9A-E92B-4252-BF21-7C9E495BB526

P433

Q35436566-C9BE7D75-6B62-4B57-9C2D-F8B757125BD7

P478

Q35436566-298A1375-575C-4218-9E1C-6F7C0D526493

P577

Q35436566-1C5726D1-38C0-49A4-A8F1-C37AD9286246

P5875

Q35436566-033C705F-3B2E-4BDF-999D-2D46959CC51A

P698

Q35436566-27CDCD79-33BA-497D-AEEE-39076E4A71A3

P932

Q35436566-0997CE61-771C-4D45-969E-5936C6EE7792

P356

PNAS.91.12.5330

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Terminal neuroendocrine differ ...... eased intracellular cyclic AMP

@en

P2093

Bang YJ

http://www.w3.org/2001/XMLSchema#string

Fang WG

http://www.w3.org/2001/XMLSchema#string

Ha MJ

http://www.w3.org/2001/XMLSchema#string

Kang WK

http://www.w3.org/2001/XMLSchema#string

Myers CE

http://www.w3.org/2001/XMLSchema#string

Nguyen P

http://www.w3.org/2001/XMLSchema#string

Niklinski WT

http://www.w3.org/2001/XMLSchema#string

Pirnia F

http://www.w3.org/2001/XMLSchema#string

Sartor O

http://www.w3.org/2001/XMLSchema#string

Sheahan MD

http://www.w3.org/2001/XMLSchema#string

P2860

A murine cDNA encodes a pan-epithelial glycoprotein that is also expressed on plasma cells

Specificity of the cAMP-induced gene exposure reaction in CHO cells

Stage-specific embryonic antigens (SSEA-3 and -4) are epitopes of a unique globo-series ganglioside isolated from human teratocarcinoma cells

Chromogranin A expression in normal and malignant human tissues

Neuroendocrine differentiation in human prostatic carcinoma.

Blood platelets express high levels of the pp60c-src-specific tyrosine kinase activity.

The chromogranins A and B: the first 25 years and future perspectives.

Transcriptional inactivation of c-myc and the transferrin receptor in dibutyryl cyclic AMP-treated HL-60 cells.

Cyclic AMP induces transforming growth factor beta 2 gene expression and growth arrest in the human androgen-independent prostate carcinoma cell line PC-3

Production and characterization of monoclonal antibodies with specificity for the S100 beta polypeptide of brain S100 fractions

P304

5330-5334

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.91.12.5330

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

91

http://www.w3.org/2001/XMLSchema#string

P577

1994-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

14995756

http://www.w3.org/2001/XMLSchema#string

P698

8202489

http://www.w3.org/2001/XMLSchema#string

P932

43988

http://www.w3.org/2001/XMLSchema#string